Showing 1211-1220 of 3024 results for "".
- COVID-19 Patient Registry for People with Autoimmune Diseases, Including MS, Launcheshttps://practicalneurology.com/news/covid-19-patient-registry-for-people-with-autoimmune-diseases-including-ms-launches/2469237/A new longitudinal study Autoimmune COVID-19 Project (NCT04344210) for individuals with multiple sclerosis (MS), arthritis, Crohn’s and colitis, and vasculitis and will track
- Diroximel Fumarate Treatment of Relapsing MS Has Improved Gastrointestinal Tolerability and Improved Quality of Lifehttps://practicalneurology.com/news/diroximel-fumarate-treatment-of-relapsing-ms-has-improved-gastrointestinal-tolerability-and-improved-quality-of-life/2469379/In EVOLVE-MS-2 (NCT03093324) trial of diroximel fumarate (Vumerity; Biogen, Cambridge, MA), recently approved for the treatment of relapsing forms of multiple sclerosis (MS), had significantly more gastrointestinal (GI) tolerability th
- First Guidelines for De-escalating and Discontinuing MS Therapies Releasedhttps://practicalneurology.com/news/first-guidelines-for-de-escalating-and-discontinuing-ms-therapies-released/2475069/A panel of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) has developed the first comprehensive guidelines for de-escalating and discontinuing disease-modifying therapies (DMTs) in individuals diagnosed with multiple sclerosis (MS). The guidelines, published in
- Researchers Find Association Between Dysregulation of Three Genes and MShttps://practicalneurology.com/news/researchers-find-association-between-dysregulation-of-three-genes-and-ms/2470082/New research published in the Annals of Clinical and Translational Neurology has identified dysregulation in three specific genes along with their expressed proteins that may be associated with multiple sclerosis (MS). The three genes were SHMT1, FAM120B, and ICA1L. As part of
- Investigational MS Treatment Diroximel Fumarate Has Improved Gastrointestinal Tolerabilityhttps://practicalneurology.com/news/investigational-ms-treatment-diroximel-fumarate-has-improved-gastrointestinal-tolerability/2468982/Topline results from the EVOLVE-MS-2 study (NCT02634307), of diroximel fumarate (ALKS8700, BIIB098; Alkermes, Waltham, MA and Biogen, Cambridge, MA) for treatment of relapsing-remitting multiple sclerosis (RRMS) have been announced. Pa
- Risk of Adult-Onset MS Associated with Maternal Pregnancy Outcomes in Studyhttps://practicalneurology.com/news/risk-of-adult-onset-ms-associated-with-maternal-pregnancy-outcomes-in-study/2485407/Individuals born large for their gestational age or exposed to maternal diabetes during pregnancy may have an increased risk for developing multiple sclerosis (MS) in adulthood, according to findings from a population-based cohort study published in JAMA Neurology. In contrast, individua
- New Consensus Statement Aims to Refine PIRA Assessment in MShttps://practicalneurology.com/news/new-consensus-statement-aims-to-refine-pira-assessment-in-ms/2483550/Although Progression Independent of Relapse Activity (PIRA) is recognized as a key driver of disability accumulation in multiple sclerosis (MS), its clinical utility has been limited by a lack of consensus definition in the field and overreliance on the Expanded Disability Status Scale (EDSS). In
- Anti-CD20 Therapies Outperform Platform DMTs in Pediatric MShttps://practicalneurology.com/news/high-efficacy-anti-cd20-vs-platform-therapies-in-prepubertal-pediatric-ms/2483537/Anti-CD20 therapies were associated with superior outcomes compared with traditional platform disease-modifying treatments (DMTs) for children with prepubertal-onset multiple sclerosis (MS) according to study results presented at the 41st Congress of the European Committee for Treatment and Resea
- Paramagnetic Rim Lesions May Support Diagnosis in People with Suspected MShttps://practicalneurology.com/news/paramagnetic-rim-lesions-show-diagnostic-value-in-multiple-sclerosis-clinics/2483418/Paramagnetic rim lesions (PRLs), which are visible on susceptibility-based MRI, may serve as a useful diagnostic marker in people undergoing evaluation for multiple sclerosis (MS), according to a new study published in Neurology. The presence of PRLs was associated with increased diagnos
- Physician Visits Increased Up to 15 Years Before MS Symptom Onsethttps://practicalneurology.com/news/physician-visits-increased-up-to-15-years-before-ms-symptom-onset/2476101/Results from a large, matched cohort study published in JAMA Network Open reveal that health care use begins to rise 14 to 15 years before the onset of the first recognized symptoms of multiple sclerosis (MS). The findings suggest a longer prodromal phase than previously understood, with